"Wolverine Stack"
BPC-157 + TB-500 ± GHK-Cu — the flagship healing stack, and the teaching case for the whole stacks section.
Evidence tier C · Not approved in Canada · Community risk: high — the risk is in the sourcing, the self-injection, and the "healing factor" framing, not in a single molecule.
C
What it is
The "Wolverine stack" is a community-named injectable combination of BPC-157 (a synthetic peptide fragment) and TB-500 (a synthetic fragment related to thymosin β4), sometimes with GHK-Cu (a copper-binding tripeptide) added. Named after the comic-book character's regeneration, it's marketed peer-to-peer for injury recovery, tendon and soft-tissue healing, and "bouncing back faster." It is the flagship of a family of blends built from the same handful of compounds — GLOW and KLOW are close relatives.
What People Use it For
• Tendon, ligament, and muscle injury recovery; post-surgical or post-training healing.
• "Prehab" / durability among lifters, endurance athletes, and combat-sports communities.
• Sold both as separate vials to combine and — increasingly — as premixed multi-peptide vials, which is a distinct and worse risk profile.
What The Evidence Shows
The gap is the whole point:
• BPC-157: promising animal data on tendon/ligament/gut healing. Human evidence is essentially absent — the one registered early-phase trial ("Bepecin," Ph1) has an unknown status, ~42 participants, and no posted results, and hasn't been updated in years. "There's a clinical trial" is technically true and practically empty.
• TB-500 / thymosin β4: the large PubMed footprint is mostly endogenous thymosin β4 biology, not trials of injected TB-500 for recovery — only a handful of human trials, none establishing the community's claimed use.
• GHK-Cu: real topical/skin and wound mechanism data; the injectable-for-systemic-healing use is not supported by human outcome trials.
• The combination itself: zero human trials. There is no study of Wolverine/GLOW/KLOW as a blend. Every claim is inferred from thin single-compound data plus anecdote. Additive benefit is assumed, not shown; additive risk is equally unstudied.
Why the evidence is thin: none of these compounds has a corporate sponsor funding Phase 2–3 trials. Thin evidence reflects who paid for research, not a proven lack of effect — but "not disproven" is not "shown to work."
Regulatory Status - Canada
None of BPC-157, TB-500, or GHK-Cu is a Health-Canada-approved therapeutic. They are sold as "research chemicals" or "not for human use" — a label that is a legal shield for the seller, not a safety statement.
US context (for readers who see it discussed): the FDA's Pharmacy Compounding Advisory Committee is scheduled to review several of these peptides (including BPC-157 and thymosin β4/TB-500) for the 503A compounding list on July 23–24, 2026 — but that is a US compounding-list question and does not change Health Canada status or make any blend approved.
Risks & Red Flags
• Unknown long-term safety for all three by injection; no controlled AE data for the combination.
• Angiogenic concern: BPC-157 and TB-500 are discussed as promoting blood-vessel growth — a theoretical flag for anyone with cancer risk that the community rarely mentions.
• Injection-site and systemic infection risk from self-injection of non-sterile, self-reconstituted product.
• GHK-Cu / copper: repeated dosing raises the question of copper load; unquantifiable with unverified product.
• Interaction/attribution problem: in a blend, a reaction can't be traced to a component, and the dose of any single peptide can't be confirmed.
The Honest Bottom Line
The community confidence in this stack is at its maximum exactly where the combination evidence is at its minimum. That's the whole tension: people trust it because other people swear by it, not because a trial ever tested it. If you strip away the "healing factor" branding, what's left is three thinly-studied compounds, injected together, from an unregulated source, with no way to attribute benefit or harm to any one of them. That doesn't mean it does nothing — it means nobody can honestly tell you what it does, and the biggest risk isn't the molecules, it's the vial you can't verify.
How To Lower Your Risk
• Recognize the evidence tier honestly: this is anecdote-grade for the combination. If you proceed, proceed knowing that — not believing there's a trial behind it.
• Single compounds over premixed blends if using at all — at least the dose of each is knowable and reactions are attributable.
• Third-party testing (independent lab COA for identity and quantity, not a vendor "99% purity" claim) is the minimum sourcing bar.
• Remember mislabeling is the #1 documented risk — independent testing of unapproved peptides finds a substantial share mislabeled, including Glow/Klow blend swaps. "99% purity" is about contaminants, not whether each peptide is at the intended dose.
• Sterile technique for any injection; never share vials; watch for injection-site infection.
• Talk to a clinician, especially with any cancer history (angiogenesis concern).
• Learn the slang glossary so you actually know what's in a blend before it's in you.
Sources
• BPC-157 human trial: registered Ph1 "Bepecin," status unknown, n≈42, no results posted, not updated since ~2016.
• TB-500 / thymosin β4: PubMed footprint dominated by endogenous-thymosin biology; only a handful of human trials, none supporting the recovery claim.
• GHK-Cu: topical/wound mechanism literature exists; no human outcome trials for injectable systemic-healing use.
• Combination (Wolverine/GLOW/KLOW): no human trials identified.
• Mislabeling/adulteration and purity-vs-potency: community-supply testing and pharmacist commentary.
Evidence tiers and the "no combination trial" finding are from this project's verification pass.
Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.